{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:09:10Z","timestamp":1788577750360,"version":"build-2803163510"},"reference-count":59,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2012]]},"DOI":"10.7883\/yoken.65.476","type":"journal-article","created":{"date-parts":[[2012,11,20]],"date-time":"2012-11-20T22:30:59Z","timestamp":1353450659000},"page":"476-482","source":"Crossref","is-referenced-by-count":60,"title":["Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes"],"prefix":"10.7883","volume":"65","author":[{"given":"Ying-Hui","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15108-2"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200411003-00008"},{"key":"3","unstructured":"3. Lindh, M., Andersson, A.-S. and Gusdal, A. (1997): Genotypes, nt1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J. Infect. Dis., 175, 1285&ndash;1293."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Beasley, R.-P., Trepo, C., Stevens, C.-E., et al. (1977): The e antigen and vertical transmission of hepatitis B surface antigen. Am. J. Epidemiol., 105, 94&ndash;98.","DOI":"10.1093\/oxfordjournals.aje.a112370"},{"key":"5","unstructured":"5. Wong, S.-N. and Lok, A.-S. (2006): Treatment of hepatitis B: who, when, and how? Arch. Intern. Med., 166, 9&ndash;12."},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.003251"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-69-10-2575"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9. Fang, Z.-L., Zhuang, H., Wang, X.-M., et al. (2004): Hepatitis B virus genotypes, phylogeny and occult infection in a region with a high incidence of hepatocellular carcinoma in China. World J. Gastroenterol., 10, 3264&ndash;3268.","DOI":"10.3748\/wjg.v10.i22.3264"},{"key":"9","unstructured":"10. Cao, G.-W. (2009): Clinical relevance and public health significance of hepatitis B virus genomic variations. World J. Gastroenterol., 22, 37&ndash;44."},{"key":"10","unstructured":"14. Arauz-Ruiz, P., Norder, H., Robertson, B.-H., et al. (2002): Genotype H: a new Amerindian genotype of hepatitis B virus related in Central America. J. Gen. Virol., 83, 2059&ndash;2073."},{"key":"11","unstructured":"15. Tran, T.-T., Trinh, T.-N. and Abe, K. (2008): New complex recombinant genotype of hepatitis B virus identified in Vietnam. J. Virol., 34, 592&ndash;594."},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00462-09"},{"key":"13","unstructured":"20. Baig, S., Siddiqui, A.-A., Ahmed, A., et al. (2007): The association of complex liver disorders with HBV genotypes prevalent in Pakistan. Virol. J., 4, 128."},{"key":"14","doi-asserted-by":"crossref","unstructured":"22. Kao, J.-H. (2011): Molecular epidemiology of hepatitis B virus. Korean J. Intern. Med., 26, 255&ndash;261.","DOI":"10.3904\/kjim.2011.26.3.255"},{"key":"15","doi-asserted-by":"crossref","unstructured":"23. Yuasa, R., Takahashi, K., Dien, B.-V., et al. (2000): Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those of acute hepatitis. J. Med. Virol., 61, 23&ndash;28.","DOI":"10.1002\/(SICI)1096-9071(200005)61:1<23::AID-JMV4>3.0.CO;2-X"},{"key":"16","unstructured":"24. Karin, K.-L., Myhre, E., Blackberg, J., et al. (2004): Clinical and serologicl variation between patients infected with different hepatitis B virus genotypes. J. Clin. Microbiol., 42, 5837&ndash;5841."},{"key":"17","doi-asserted-by":"crossref","unstructured":"25. Victoria, F.-S., deOliverira, C.-M., Victoria, M.-B., et al. (2008): Characterization of HBeAg-negative chronic hepatitis B in Western Brazilian Amazonia. Brazil. J. Infect. Dis., 12, 27&ndash;37.","DOI":"10.1590\/S1413-86702008000100008"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.11.1630"},{"key":"19","doi-asserted-by":"crossref","unstructured":"27. Maeshiro, T., Arakaki, S., Watanabe, T., et al. (2007): Different natural course of chronic hepatitis B with genotypes B and C after the fourth decade of life. World J. Gastroenterol., 13, 4560&ndash;4565.","DOI":"10.3748\/wjg.v13.i34.4560"},{"key":"20","unstructured":"28. Tonetto, D.-A., Goncakes, N.-S., Fais, V.-C., et al. (2009): Hepatitis B virus: molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of Brazil. BMC Infect. Dis., 9, 149."},{"key":"21","doi-asserted-by":"crossref","unstructured":"29. Mojiri, A., Abbas, B.-B., Saberifirozi, M., et al. (2008): Hepatitis B virus genotypes in Southwest Iran: molecular, serological and clinical outcomes. World J. Gastroenterol., 14, 1510&ndash;1513.","DOI":"10.3748\/wjg.14.1510"},{"key":"22","doi-asserted-by":"crossref","unstructured":"30. Ribeiro, R.-M., Germanidis, G., Power, K.-A., et al. (2010): Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J. Infect. Dis., 202, 1309&ndash;1317.","DOI":"10.1086\/656528"},{"key":"23","doi-asserted-by":"crossref","unstructured":"32. Furusyo, N., Nakashima, H., Kashiwagi, K., et al. (2002): Clinical outcomes of hepatitis B virus (HBV) genotype B and C in Japanese patients with chronic HBV infection. Am. J. Trop. Med. Hyg., 67, 151&ndash;157.","DOI":"10.4269\/ajtmh.2002.67.151"},{"key":"24","doi-asserted-by":"crossref","unstructured":"33. Kao, J.-H., Chen, P.-J., Lai, M.-Y., et al. (2002): Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J. Clin. Microbiol., 40, 1207&ndash;1209.","DOI":"10.1128\/JCM.40.4.1207-1209.2002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"34. Yu, M.-W., Yeh, S.-H., Chen, P.-J., et al. (2005): Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J. Natl. Cancer Inst., 97, 265&ndash;272.","DOI":"10.1093\/jnci\/dji043"},{"key":"26","doi-asserted-by":"crossref","unstructured":"35. Chen, C.H., Lee, C.-M., Lai, S.-N., et al. (2005): Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J. Clin. Microbiol., 43, 6000&ndash;6006.","DOI":"10.1128\/JCM.43.12.6000-6006.2005"},{"key":"27","unstructured":"36. Orito, E., Mizokami, M., Sakugawa, H., et al. (2002): A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Hepatology, 33, 218&ndash;223."},{"key":"28","unstructured":"38. Lusida, M.-I., Nugrahaputra, V.-E., Soetjipto., et al. (2008): Novel subtypes of hepatitis B virus genotypes C and D in Papua, Indonesia. J. Clin. Microbiol., 46, 2160&ndash;2166."},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50053"},{"key":"30","doi-asserted-by":"crossref","unstructured":"40. Fujie, H., Moriya, K., Shintani, Y., et al. (2001): Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology, 120, 1564&ndash;1565.","DOI":"10.1053\/gast.2001.24501"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70261-7"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1086\/382885"},{"key":"33","doi-asserted-by":"crossref","unstructured":"43. Wang, Z., Tanaka, Y., Huang, Y., et al. (2007): Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J. Clin. Microbiol., 45, 1491&ndash;1496.","DOI":"10.1128\/JCM.02157-06"},{"key":"34","doi-asserted-by":"crossref","unstructured":"44. Akuta, N. and Kumada, H. (2005): Influence of hepatitis B virus genotype on the response to antiviral therapies. J. Antimicrobiol. Chem., 55, 139&ndash;142.","DOI":"10.1093\/jac\/dkh533"},{"key":"35","unstructured":"45. Buster, E.H.C.J. and Janssen, H.L.A. (2006): Antiviral treatment for chronic hepatitis B virus infection-immune modulation or viral suppression? Netherlands J. Med., 64, 175&ndash;185."},{"key":"36","unstructured":"46. Haria, M. and Benfield, P. (1995): Interferon-alpha-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs, 30, 873&ndash;896."},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80135-X"},{"key":"38","doi-asserted-by":"crossref","unstructured":"48. Wai, C.-T., Chu, C.-S., Hussain, M., et al. (2002): HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology, 36, 1425&ndash;1430.","DOI":"10.1002\/hep.1840360619"},{"key":"39","unstructured":"49. Ma, J.-C., Wang, L.-W., Li, X.-J., et al. (2007): Relationship between HBV genotypes and antiviral therapeutic efficacy of interferon-alpha. Hepatobiliary Pancreat. Dis. Int., 6, 166&ndash;171."},{"key":"40","unstructured":"50. Craxi, A. and Cooksley, W.-G. (2003): Pegylated interferon for chronic hepatitis B virus. Antiviral. Res., 60, 87&ndash;89."},{"key":"41","doi-asserted-by":"crossref","unstructured":"51. Cooksley, W.-G., Piratvisuth, T., Lee, S.-D., et al. (2003): Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Virol. Hepat., 10, 298&ndash;305.","DOI":"10.1046\/j.1365-2893.2003.00450.x"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"43","doi-asserted-by":"crossref","unstructured":"53. Flink, H.-J, van Zonneveld, M., Hansen, B.-E., et al. (2006): Treatment with Peg-interferon &alpha;-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol., 101, 297&ndash;303.","DOI":"10.1111\/j.1572-0241.2006.00418.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"54. Jassen, H.-L., Berk, L., Vermeulen, M., et al. (1990): Seizures associated with low-dose alpha-interferon. Lancet, 336, 1580.","DOI":"10.1016\/0140-6736(90)93356-T"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80371-2"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26512"},{"key":"47","doi-asserted-by":"crossref","unstructured":"57. Moskoviz, D.-N., Osiowy, C., Giles, E., et al. (2005): Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J. Virol. Hepat., 12, 398&ndash;404.","DOI":"10.1111\/j.1365-2893.2005.00613.x"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80372-4"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.8559"},{"key":"50","doi-asserted-by":"crossref","unstructured":"60. Yuen, M.-F., Wong, D.-K., Sablon, E., et al. (2003): Hepatitis B virus genotype B and C do not affect the antiviral response to lamivudine. Antivir. Ther., 8, 531&ndash;534.","DOI":"10.1177\/135965350300800610"},{"key":"51","unstructured":"61. Wang, G.-Y., Zhu,W.-J., Yang, X.-L., et al. (2005): YMDD mutation of hepatitis B virus and genotyping in Guiyang region. Chin. J. Hepatol., 13, 193&ndash;195 (in Chinese)."},{"key":"52","doi-asserted-by":"crossref","unstructured":"62. Akuta, N., Suzuki, F., Kobayashi, M., et al. (2003): The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol., 38, 315&ndash;321.","DOI":"10.1016\/S0168-8278(02)00410-5"},{"key":"53","doi-asserted-by":"crossref","unstructured":"63. Rizzetto, M., Tassopoulos, N.-C., Goldin, R.-D., et al. (2005): Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J. Hepatol., 42, 173&ndash;179.","DOI":"10.1016\/j.jhep.2004.10.006"},{"key":"54","doi-asserted-by":"crossref","unstructured":"64. Brunetto, M.-A. and Bonino, F. (2004): Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences. Curr. Pharm. Des., 10, 2063&ndash;2075.","DOI":"10.2174\/1381612043384277"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00246-X"},{"key":"56","doi-asserted-by":"crossref","unstructured":"67. Lagget, M. and Rizzetto, M. (2003): Current pharmacotherapy for the treatment of chronic hepatitis B. Expert. Opin. Pharmacother., 4, 1821&ndash;1827.","DOI":"10.1517\/14656566.4.10.1821"},{"key":"57","unstructured":"68. Economou, M., Manolakopoulos, S., Trikalinos, T.-A., et al. (2005): Interferon-&alpha; plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J. Gastroenterol., 11, 5882&ndash;5887."},{"key":"58","doi-asserted-by":"crossref","unstructured":"69. Schlaak, J.-F., Tully, G., L&ouml;hr, H.-F., et al. (1999): HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin. Exp. Immunol., 115, 508&ndash;514.","DOI":"10.1046\/j.1365-2249.1999.00812.x"},{"key":"59","doi-asserted-by":"crossref","unstructured":"71. Shi, Y.-H. and Shi, C.-H. (2009): Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol., 15, 3099&ndash;3105.","DOI":"10.3748\/wjg.15.3099"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T22:06:29Z","timestamp":1687817189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/65\/6\/65_476\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.65.476","relation":{},"ISSN":["1344-6304"],"issn-type":[{"value":"1344-6304","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}